Viral Hepatitis

You have full text access to this OnlineOpen article

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection†

  1. Yves Horsmans1,
  2. Thomas Berg2,
  3. Jean-Pierre Desager1,
  4. Tobias Mueller2,
  5. Eckart Schott2,
  6. Simon P. Fletcher3,
  7. Kevin R. Steffy3,
  8. Lisa A. Bauman3,
  9. Bradley M. Kerr3,
  10. Devron R. Averett3,‡,*

Article first published online: 22 AUG 2005

DOI: 10.1002/hep.20839

Issue

Hepatology

Hepatology

Volume 42, Issue 3, pages 724–731, September 2005

Additional Information

How to Cite

Horsmans, Y., Berg, T., Desager, J.-P., Mueller, T., Schott, E., Fletcher, S. P., Steffy, K. R., Bauman, L. A., Kerr, B. M. and Averett, D. R. (2005), Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology, 42: 724–731. doi: 10.1002/hep.20839

Author Information

  1. 1

    Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Unit de Pharmacologie Clinique, Brussels, Belgium

  2. 2

    Universitätsklinikum Charité, Humboldt-Unversität zu Berlin, Campus Virchow, Hepatologie und Gastroenterologie, Berlin, Germany

  3. 3

    Anadys Pharmaceuticals, Inc., San Diego, CA

  1. ‡

    fax: 858-527-1540

*Anadys Pharmaceuticals, Inc., San Diego, CA

  1. †

    Potential conflict of interest: DR Averett, SP Fletcher, BM Kerr, LA Bauman, and KR Steffy own stock in and are employed by Anadys Pharmaceuticals. Y Horsmans, T Berg, JP Desager, T Mueller, and E Schott were compensated by Anadys for clinical study services. T Berg and E Schott received a research grant from Anadys. Y Horsmans and T Berg are consultants to Anadys.

Publication History

  1. Issue published online: 22 AUG 2005
  2. Article first published online: 22 AUG 2005
  3. Manuscript Accepted: 24 JUN 2005
  4. Manuscript Received: 31 JAN 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (307K)

References

  • 1
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 1147-1171.
    Direct Link:
  • 2
    Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-2100.
  • 3
    National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002; 123: 2082-2099.
  • 4
    Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996; 8: 324-328.
  • 5
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
  • 6
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  • 7
    Pawlotsky JM, McHutchison JG. Hepatitis C: development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. HEPATOLOGY 2004; 39: 554-567.
    Direct Link:
  • 8
    Lindenbach BD, Rice CM. Evasive maneuvers by hepatitis C virus. HEPATOLOGY 2003; 38: 769-771.
    Direct Link:
  • 9
    Trozzi C, Bartholomew L, Ceccacci A, Biasiol G, Pacini L, Altamura S, et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003; 77: 3669-3679.
  • 10
    Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
  • 11
    Netea MG, van der Graaf C, Van der Meer JW, Kullberg BJ. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol 2004; 75: 749-755.
  • 12
    Beutler B. Inferences, questions and possibilities in toll-like receptor signalling. Nature 2004; 430: 257-263.
  • 13
    O'Neill LA. Immunology. After the toll rush. Science 2004; 303: 1481-1482.
  • 14
    Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of toll-like receptor 7. Proc Natl Acad Sci U S A 2003; 100: 6646-6651.
  • 15
    Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T, et al. The toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003; 33: 2987-2997.
    Direct Link:
  • 16
    Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85-95.
  • 17
    Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
  • 18
    Nagahara K, Anderson JD, Kini GD, Dalley NK, Larson SB, Smee DF, et al. Thiazolo[4,5-d]pyrimidine nucleosides: the synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents. J Med Chem 1990; 33: 407-415.
  • 19
    Smee DF, Alaghamandan HA, Cottam HB, Sharma BS, Jolley WB, Robins RK. Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent. Antimicrob Agents Chemother 1989; 33: 1487-1492.
  • 20
    Smee DF, Alaghamandan HA, Cottam HB, Jolley WB, Robbins RK. Antiviral activity of the novel immune modulator 7-thia-8-oxoguanosine. J Biol Response Mod 1990; 9: 24-32.
  • 21
    Smee DF, Huffman JH, Gessaman AC, Huggins JW, Sidwell RW. Prophylactic and therapeutic activities of 7-thia-8-oxoguanosine against Punta Toro virus infections in mice. Antiviral Res 1991; 15: 229-239.
  • 22
    Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alpha-2b plus ribavirin. HEPATOLOGY 2002; 35: 930-936.
    Direct Link:
  • 23
    Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-567.
  • 24
    Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. HEPATOLOGY 2003; 37: 1351-1358.
    Direct Link:
  • 25
    Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C; a randomized, controlled study. Antivir Ther 2004; 9: 491-497.
  • 26
    Solinas A, Cossu P, Poddighe P, Tocco A, Deplano A, Garrucciu G, et al. Changes of serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C. Liver 1993; 13: 253-258.
  • 27
    Schenker S, Cutler D, Finch J, Tamburro CH, Affrime M, Sabo R, et al. Activity and tolerance of a continuous subcutaneous infusion of interferon-alpha2b in patients with chronic hepatitis C. J Interferon Cytokine Res 1997; 17: 665-670.
  • 28
    Murashima S, Kumashiro R, Ide T, Miyajima I, Hino T, Koga Y, et al. Effect of interferon treatment on serum 2',5'-oligoadenylate synthetase levels in hepatitis C-infected patients. J Med Virol 2000; 62: 185-190.
    Direct Link:
  • 29
    MacQuillan GC, Mamotte C, Reed WD, Jeffrey GP, Allan JE. Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J Med Virol 2003; 70: 219-227.
    Direct Link:
  • 30
    Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3: 175-87.
  • 31
    Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195-3204.
  • 32
    Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46: 563-570.
    Direct Link:
  • 33
    Hong Z, Cameron CE. Pleiotropic mechanisms of ribavirin antiviral activities. Prog Drug Res 2002; 59: 41-69.
  • 34
    Hong Z. The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact? HEPATOLOGY 2003; 38: 807-810.
  • 35
    Vollmer J, Rankin R, Hartmann H, Jurk M, Samulowitz U, Wader T, et al. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother 2004: 48: 2314-2317.
  • 36
    De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30: 115-133.
  • 37
    Pockros PJ, Patel K, O'Brien C, Tong M, Smith C, Rustgi V, et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. HEPATOLOGY 2003; 37: 1368-1374.
    Direct Link:
  • 38
    Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002; 5: 375-388.
  • 39
    Zuany-Amorim C, Hastewell J, Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov 2002; 1: 797-807.
  • 40
    Lawton JA, Ghosh P. Novel therapeutic strategies based on toll-like receptor signaling. Curr Opin Chem Biol 2003; 7: 446-451.
  • 41
    O'Neill LA. Therapeutic targeting of toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 2003; 3: 396-403.
  • 42
    Tran H, Moreno G, Shumack S. Imiquimod as a dermatological therapy. Expert Opin Pharmacother 2004; 5: 427-438.
  • 43
    Pockros P, Tong M, Wright T. A phase IIa placebo-controlled, double blind trial to determine the safety, tolerability, and pk/pd of an oral interferon inducer. Gastroenterology 2003; 124(Suppl 1): 76A.
View Full Article (HTML) Get PDF (307K)